Clinical Trial Update: Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring [Phase 3]

View source ↗

Summary

Phase 3 study of MB-102 (Relmapirazin) using the MediBeacon Transdermal GFR measurement system has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Kidney Injury

Drugs mentioned

• MB-102 (Relmapirazin) (Relmapirazin)

Snippet

Sponsor: MediBeacon | Conditions: Kidney Diseases, Kidney Injury | Phase 3 | Status: COMPLETED | Results posted: 2025-03-28